CTLA-4 blockades can enhance the metabolic fitness of CD8+T cells and destabilize Tregs in glycolysis-defective tumors, indicating that the combination of CTLA-4 blockers and glycolysis inhibitors is a promising strategy in cancer (Zappasodi et al., 2021). The gene discussed is CD8A; the disease is cancer.